Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

• Disease Name: Kanzaki Disease
• MONDO ID: (if available)
• Category: Mendelian

Research Objectives

Please provide a comprehensive research report on Kanzaki Disease covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

• What is the disease? Provide a concise overview.
• What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
• What are the common synonyms and alternative names?
• Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

• Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
• Risk Factors:

  Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases

• Genetic risk factors (causal variants, susceptibility loci, modifier genes)
• Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
• Protective Factors:

  Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases

• Genetic protective factors (protective variants, modifier alleles)
• Environmental protective factors (diet, lifestyle, exposures that reduce risk)
• Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

  Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

• Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

  Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene

• Pathogenic Variants:
• Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
• Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
• Variant type/class (missense, frameshift, nonsense, splice-site, structural)
• Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
• Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
• Functional consequences (loss of function, gain of function, dominant negative)
• Modifier Genes: Genes that modify disease severity or expression
• Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

  Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

• Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

  Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

• Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

  Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases

• Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

  Search first: CDC databases, WHO, PubMed, NHANES

• Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

  Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

• Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

  Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc

• Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

  Search first: Gene Ontology (GO), Reactome, KEGG, PubMed

• Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

  Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold

• Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

  Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA

• Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

  Search first: ImmPort, Immunome Database, IEDB, Gene Ontology

• Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

  Search first: PubMed, Gene Ontology, Reactome

• Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

  Search first: BRENDA, UniProt, KEGG, OMIM, PubMed

• Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

  Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

• Molecular Profiling (if available):
• Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
• Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
• Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
• Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
• Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
• Advanced Technologies (if applicable):
• Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
• Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
• Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
• Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

• Organ Level:
• Primary organs directly affected
• Secondary organ involvement (complications, secondary effects)
• Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

  Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT

• Tissue and Cell Level:
• Specific tissue types affected (epithelial, connective, muscle, nervous)
• Specific cell populations targeted (with Cell Ontology terms)

  Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB

• Subcellular Level:
• Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

  Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas

• Localization:
• Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
• Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

• Onset:
• Typical age of onset (congenital, pediatric, adult, geriatric)
• Onset pattern (acute, subacute, chronic, insidious)

  Search first: OMIM, Orphanet, HPO, PubMed

• Progression:
• Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
• Progression rate (rapid, slow, variable)
• Disease course pattern (episodic, relapsing-remitting, progressive, stable)
• Disease duration (self-limited, chronic lifelong)

  Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM

• Patterns:
• Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
• Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

• Epidemiology:
• Prevalence (cases per 100,000 at given time)
• Incidence (new cases per 100,000 per year)

  Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries

• For Genetic Etiology:
• Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
• Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
• Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
• Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
• Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
• Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
• Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
• Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
• Population Demographics:
• Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
• Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
• Geographic distribution of specific variants
• Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
• Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

• Clinical Tests:
• Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
• Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
• Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
• Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
• Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
• Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
• Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
• Genetic Testing:

  Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen

• Overview of recommended genetic testing approach
• Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
• Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
• Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
• Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
• Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
• Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
• FISH > Search first: ClinVar, cytogenetics databases, PubMed
• Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
• Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
• Omics-Based Diagnostics (if applicable):
• RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
• Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
• Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
• Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
• Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
• Clinical Criteria:
• Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
• Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
• Screening:
• Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

• Survival and Mortality:
• Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
• Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
• Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
• Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
• Morbidity and Function:
• Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
• Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
• Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
• Disease Course:
• Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
• Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
• Prediction:
• Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
• Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

• Pharmacotherapy:
• Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
• Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
• Advanced Therapeutics:
• Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
• Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
• RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
• Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
• Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
• Surgical and Interventional:
• Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
• Supportive and Rehabilitative:
• Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
• Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
• Experimental:
• Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
• Treatment Outcomes:
• Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
• Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
• Treatment Strategy:
• Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
• Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
• Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.

13. Prevention

• Prevention Levels:
• Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
• Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
• Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
• Immunization: Vaccine strategies (if applicable)

  Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database

• Screening and Early Detection:
• Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
• Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
• Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
• Behavioral Interventions: Lifestyle modifications to reduce risk

  Search first: CDC, WHO, behavioral intervention databases, Cochrane Library

• Counseling: Genetic counseling (risk assessment, family planning guidance)

  Search first: NSGC resources, ACMG guidelines, GeneReviews

• Public Health:
• Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
• Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
• Prophylaxis: Preventive medications or procedures

  Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

• Taxonomy: Species affected (with NCBI Taxon identifiers)

  Search first: NCBI Taxonomy

• Breed: Specific breeds affected (with VBO identifiers if applicable)

  Search first: VBO (Vertebrate Breed Ontology)

• Gene: Orthologous genes in other species (with NCBI Gene IDs)

  Search first: NCBI Gene

• Natural Disease:
• Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
• Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
• Comparative Biology:
• Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
• Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
• Transmission (if applicable):
• Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
• Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

• Model Types:
• Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
• Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
• Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
• Genetic Models:
• Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
• Model Characteristics:
• Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
• Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
• Applications:
• Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
• Resources:
• Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

• Cite primary literature (PMID preferred) for all mechanistic and clinical claims
• Prioritize recent reviews and landmark papers
• Include direct quotes from abstracts where possible to support key statements
• Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Comprehensive Research Report: Kanzaki Disease (Schindler disease type II; α-N-acetylgalactosaminidase deficiency type 2)

Executive summary

Kanzaki disease is an ultra-rare, autosomal recessive lysosomal storage disorder (LSD) on the Schindler disease spectrum caused by biallelic pathogenic variants in NAGA, encoding the lysosomal exoglycosidase α-N-acetylgalactosaminidase (α-NAGA/α-NAGAL; EC 3.2.1.49). The adult-onset phenotype is classically dominated by angiokeratoma corporis diffusum, lymphedema, sensorineural hearing loss, vertigo, and peripheral neuropathy, with variable cognitive/white matter involvement. Diagnosis relies on low α-NAGA enzymatic activity, urinary oligosaccharide/glycopeptide abnormalities, and confirmatory molecular testing. No disease-modifying therapy is established; management is supportive, with pharmacological chaperones discussed as theoretical/experimental options. (castro2019anewcase pages 1-3, rossor2024theevolvingspectrum pages 10-12, rossor2024theevolvingspectrum media e968f4f1, groopman2024assessmentofgenes pages 8-11)

1. Disease information

1.1 What is the disease? (overview)

Schindler disease is an autosomal recessive LSD caused by defective or absent α-NAGA activity, with three main phenotypes (types I–III). Type II is Kanzaki disease, an adult-onset, typically milder phenotype compared with infantile neuroaxonal dystrophy (type I). (castro2019anewcase pages 1-3, asadi2021theroleof pages 1-3)

A representative adult case (68-year-old man) presented with axonal/demyelinating polyneuropathy, sensorineural hearing loss, chronic lymphedema, angiokeratoma corporis diffusum, and carpal tunnel syndrome, and molecular testing confirmed a homozygous nonsense variant in NAGA. (castro2019anewcase pages 1-3, castro2019anewcase pages 3-3)

1.2 Key identifiers (and gaps in retrieved sources)

Table: This table summarizes the main names and ontology/database identifiers retrieved for Kanzaki disease, including its relationship to Schindler disease type II and alpha-N-acetylgalactosaminidase deficiency type 2. It highlights which identifiers were directly supported by retrieved evidence and which require follow-up database queries.

Key identifiers supported in retrieved evidence include: - OMIM: 609242 (Kanzaki disease) (rossor2024theevolvingspectrum pages 10-12, rossor2024theevolvingspectrum media e968f4f1) - MONDO:0012222 (α-N-acetylgalactosaminidase deficiency type 2), with parent term MONDO:0017779 (α-N-acetylgalactosaminidase deficiency) (OpenTargets Search: Kanzaki disease,Schindler disease-NAGA)

ICD-10/ICD-11/MeSH/Orphanet identifiers were not present in the retrieved full-text excerpts, and would require direct database queries. (OpenTargets Search: Kanzaki disease,Schindler disease-NAGA)

1.3 Synonyms / alternative names

Kanzaki disease is consistently treated as synonymous with: - Schindler disease type II (asadi2021theroleof pages 1-3, castro2019anewcase pages 1-3) - α-N-acetylgalactosaminidase deficiency type 2 (OpenTargets Search: Kanzaki disease,Schindler disease-NAGA)

1.4 Evidence sources (patient-level vs aggregated)

• Patient-level: case report evidence including detailed phenotyping and a confirmed NAGA variant (e.g., the 68-year-old case). (castro2019anewcase pages 1-3, castro2019anewcase pages 3-3)
• Aggregated: ClinGen gene curation framework (2024), Open Targets/MONDO mapping, and expert reviews/tables. (groopman2024assessmentofgenes pages 8-11, OpenTargets Search: Kanzaki disease,Schindler disease-NAGA, rossor2024theevolvingspectrum pages 10-12)

2. Etiology

2.1 Primary causal factors

Genetic cause: biallelic pathogenic variants in NAGA lead to loss of α-NAGA function and lysosomal substrate accumulation. (castro2019anewcase pages 1-3, asadi2021theroleof pages 1-3, groopman2024assessmentofgenes pages 8-11)

2.2 Risk factors

• Genetic: autosomal recessive inheritance; affected individuals carry two pathogenic alleles. (asadi2021theroleof pages 1-3, rossor2024theevolvingspectrum pages 10-12)
• Modifier factors: evidence suggests marked genotype–phenotype variability; α-NAGA deficiency alone may not fully explain clinical heterogeneity, and residual enzyme activity may not correlate tightly with severity. (lukacs2022oligosaccharidosesandsialic pages 1-3, sakuraba2004structuralandimmunocytochemical pages 1-2)
• ABO blood group A: one clinical source notes that blood group A may confer worse prognosis because the A antigen terminal residue is a substrate for α-NAGA (uncleaved in deficiency). (castro2019anewcase pages 1-3)

2.3 Protective factors / gene–environment interactions

No protective environmental or genetic factors, or gene–environment interactions, were identified in the retrieved sources.

3. Phenotypes

3.1 Core phenotype spectrum (adult Kanzaki disease)

A recent neuropathy-focused review lists Kanzaki disease (OMIM 609242; AR; NAGA) with: adult-onset diffuse angiokeratoma, sensorineural hearing loss, recurrent vertigo, sensory-motor axonal neuropathy, and periventricular white matter abnormalities on MRI. (rossor2024theevolvingspectrum pages 10-12, rossor2024theevolvingspectrum media e968f4f1)

A clinical case report further emphasizes lymphedema and systemic features, and provides histologic confirmation of angiokeratomas. (castro2019anewcase pages 1-3)

Table: This table summarizes the major reported clinical phenotypes of Kanzaki disease (Schindler disease type II), emphasizing adult-onset cutaneous, neurologic, lymphatic, and imaging findings. It is designed to support phenotype curation with suggested HPO mappings and source-linked evidence.

3.2 Age of onset, progression, severity

• Onset: Kanzaki disease is typically adult-onset. (castro2019anewcase pages 1-3, rossor2024theevolvingspectrum pages 10-12)
• Course: can be chronic/progressive for some manifestations (e.g., slowly progressive lymphedema in a documented adult). (castro2019anewcase pages 3-3)
• Severity: variable; some patients show mild cognitive issues, whereas others have prominent neuropathy/hearing loss/skin findings. (makridou2025mappinglysosomalstorage pages 10-12, rossor2024theevolvingspectrum pages 10-12)

3.3 Quality of life impact

Direct QoL instrument data (e.g., SF-36/EQ-5D) were not found in retrieved sources. However, neuropathic pain and progressive lymphedema can plausibly impair function; one case required analgesia on demand for neuropathic pain. (castro2019anewcase pages 1-3)

4. Genetic / molecular information

4.1 Causal gene

• NAGA encodes α-N-acetylgalactosaminidase (α-NAGAL/α-NAGA); deficiency causes the Schindler/Kanzaki spectrum. (asadi2021theroleof pages 1-3, castro2019anewcase pages 1-3, OpenTargets Search: Kanzaki disease,Schindler disease-NAGA)

4.2 Gene–disease validity (authoritative assessment)

A 2024 ClinGen Lysosomal Disease Gene Curation Expert Panel (LD GCEP) assessment classifies NAGA–α-N-acetylgalactosaminidase deficiency (MONDO:0017779) as “Definitive.” It reports 9 probands supporting genetic evidence and additional experimental evidence (biochemical function and non-human model), while emphasizing that clinical expressivity ranges from asymptomatic to neurological manifestations. (groopman2024assessmentofgenes pages 8-11)

4.3 Pathogenic variants and functional consequences

A curated subset of reported variants and associations is summarized below.

Table: This table summarizes reported disease-associated NAGA variants relevant to the Schindler/Kanzaki spectrum, linking each variant to phenotype and available functional evidence. It is useful for rapid curation of variant-level molecular and clinical annotations, especially where genotype-phenotype correlation is complex.

Key mechanistic points: - Disease-causing variants can impair catalysis (e.g., active-site residues) or protein folding/stability (buried-core mutations) or post-translational maturation (e.g., truncations). (clark2009the1.9a pages 5-7, clark2009the1.9a pages 4-5) - A confirmed adult Kanzaki-compatible case carried c.577G>T (p.Glu193*). (castro2019anewcase pages 1-3, castro2019anewcase pages 3-3)

4.4 Molecular/biochemical biomarkers

• Enzyme activity: diminished α-NAGA activity on blood testing is used clinically. (castro2019anewcase pages 1-3, castro2019anewcase pages 3-3)
• Urine: glycopeptiduria may be detected; broader urinary oligosaccharide/glycopeptide abnormalities have been reported in α-NAGA deficiency. (castro2019anewcase pages 1-3, sakuraba2004structuralandimmunocytochemical pages 1-2, keulemans1996humanalphanacetylgalactosaminidase(alphanaga) pages 3-4)
• Cellular storage: immunocytochemistry supports lysosomal accumulation of Tn-antigen (GalNAcα-O-Ser/Thr) in Kanzaki patient fibroblasts. (makridou2025mappinglysosomalstorage pages 10-12, sakuraba2004structuralandimmunocytochemical pages 1-2)

4.5 Epigenetics / chromosomal abnormalities

No epigenetic or cytogenetic abnormalities were identified in the retrieved sources for Kanzaki disease.

5. Environmental information

No environmental, lifestyle, or infectious triggers were identified in the retrieved sources; Kanzaki disease is primarily Mendelian (autosomal recessive) and mechanistically enzymatic/lysosomal. (asadi2021theroleof pages 1-3, rossor2024theevolvingspectrum pages 10-12)

6. Mechanism / pathophysiology

6.1 Causal chain (enzyme deficiency → storage → tissue dysfunction)

1) Biallelic NAGA variants reduce α-NAGA abundance or activity. (asadi2021theroleof pages 1-3, groopman2024assessmentofgenes pages 8-11) 2) α-NAGA normally degrades glycopeptides (including Tn-antigen); loss of function causes lysosomal accumulation of undegraded substrates. (makridou2025mappinglysosomalstorage pages 10-12, sakuraba2004structuralandimmunocytochemical pages 1-2) 3) Multi-tissue substrate storage is consistent with systemic findings (skin, peripheral nerves, lymphatic system, and sometimes CNS/white matter). (castro2019anewcase pages 1-3, rossor2024theevolvingspectrum pages 10-12)

A clinical source also describes failure to hydrolyze terminal residues leading to intracellular accumulation of classes of glycoconjugates/lipids (galactose oligosaccharides, galactomannans, galactolipids). (castro2019anewcase pages 1-3)

6.2 Structural biology (expert mechanistic evidence)

High-resolution structural work provides a detailed catalytic framework: - Human α-NAGAL is a homodimer with a TIM-barrel catalytic domain; catalysis proceeds by a double-displacement mechanism with D156 as nucleophile and D217 as acid/base. Substrate specificity for α-GalNAc involves interactions with S188/A191/R213 and ligand-induced rearrangements in the active site. (clark2009the1.9a pages 2-4, clark2009the1.9a pages 4-5) - Mapping pathogenic variants onto the structure supports that many mutations destabilize the core or disrupt essential catalytic residues and disulfide networks, offering a mechanistic basis for chaperone strategies. (clark2009the1.9a pages 5-7, clark2009the1.9a pages 21-22)

6.3 Genotype–phenotype complexity (expert analysis)

Multiple sources emphasize a paradoxical or weak relationship between residual enzyme activity and clinical severity, implying modifiers beyond NAGA alone. (lukacs2022oligosaccharidosesandsialic pages 1-3, sakuraba2004structuralandimmunocytochemical pages 1-2)

6.4 Suggested ontology terms

• GO (process): lysosomal glycoprotein catabolic process; glycosphingolipid catabolic process; lysosome organization (supported broadly by lysosomal storage mechanism). (castro2019anewcase pages 1-3, makridou2025mappinglysosomalstorage pages 10-12)
• GO (cellular component): lysosome. (makridou2025mappinglysosomalstorage pages 10-12)
• CL (cell types implicated by storage evidence): vascular endothelial cell, fibroblast, pericyte, eccrine sweat gland cell (storage of Tn-antigen reported in these cell types). (sakuraba2004structuralandimmunocytochemical pages 5-7)

7. Anatomical structures affected

7.1 Organ/system level

• Skin: angiokeratoma corporis diffusum is a central clinical manifestation. (castro2019anewcase pages 1-3, rossor2024theevolvingspectrum pages 10-12)
• Peripheral nervous system: sensory-motor axonal neuropathy/polyneuropathy. (rossor2024theevolvingspectrum media e968f4f1, castro2019anewcase pages 1-3)
• Auditory/vestibular system: sensorineural hearing loss and recurrent vertigo. (rossor2024theevolvingspectrum media e968f4f1, castro2019anewcase pages 1-3)
• Lymphatic system: chronic lymphedema; lymphadenopathy reported. (castro2019anewcase pages 1-3, makridou2025mappinglysosomalstorage pages 10-12)
• Central nervous system: periventricular white matter abnormalities may be present on MRI; cognitive decline can be mild. (rossor2024theevolvingspectrum media e968f4f1, makridou2025mappinglysosomalstorage pages 10-12)

7.2 Suggested UBERON mappings (examples)

• Skin: UBERON:0002097
• Peripheral nerve: UBERON:0001021
• Inner ear: UBERON:0001768
• Lymph node: UBERON:0000029
• Cerebral white matter: UBERON:0002319 (These are ontology suggestions; not explicitly enumerated in retrieved texts.)

7.3 Subcellular localization

The relevant compartment is the lysosome. (makridou2025mappinglysosomalstorage pages 10-12)

8. Temporal development

8.1 Onset pattern

Kanzaki disease is adult-onset in contrast to infantile Schindler type I. (castro2019anewcase pages 1-3, rossor2024theevolvingspectrum pages 10-12)

8.2 Progression / staging

Formal stage systems were not identified. A case report documents stability of some features (neuropathy/hearing loss/angiokeratomas) with slowly progressive lymphedema. (castro2019anewcase pages 3-3)

9. Inheritance and population

9.1 Inheritance

• Autosomal recessive inheritance is consistently reported for Kanzaki disease. (asadi2021theroleof pages 1-3, rossor2024theevolvingspectrum pages 10-12)

9.2 Epidemiology

Kanzaki disease is exceptionally rare. A 2019 case report states: “To our knowledge, fewer than 20 cases have been described to date.” (castro2019anewcase pages 1-3)

Robust prevalence/incidence estimates were not identified in retrieved sources.

10. Diagnostics

10.1 Clinical tests

• Enzyme assay: blood testing showing diminished α-NAGA activity is a key biochemical diagnostic. (castro2019anewcase pages 1-3, castro2019anewcase pages 3-3)
• Urine testing: may reveal glycopeptiduria and oligosaccharide/glycopeptide abnormalities. (castro2019anewcase pages 1-3, keulemans1996humanalphanacetylgalactosaminidase(alphanaga) pages 3-4)

10.2 Genetic testing

• Molecular testing of NAGA is described as the gold standard in a clinical report (PCR-based testing in that context), confirming diagnosis in an adult Kanzaki-compatible case. (castro2019anewcase pages 1-3, castro2019anewcase pages 3-3)

10.3 Differential diagnosis

Kanzaki disease may be confused with other LSDs such as Fabry disease due to angiokeratomas; one patient had normal α-galactosidase activity, helping exclude Fabry. (castro2019anewcase pages 3-3)

11. Outcome / prognosis

Evidence is limited; adult-onset Kanzaki disease can be chronic and progressive in some domains (e.g., lymphedema). A clinical report suggests worse prognosis for blood group A patients. Survival statistics were not found in retrieved sources. (castro2019anewcase pages 1-3, castro2019anewcase pages 3-3)

12. Treatment

12.1 Standard of care (current real-world implementation)

Across sources, the only established care is supportive/symptomatic. - A case report states: “The only treatment for this disease consists of support measures and symptomatic treatment,” and the patient used analgesia for neuropathic pain. (castro2019anewcase pages 1-3) - Another review-like source emphasizes supportive multidisciplinary management and genetic counseling. (asadi2021theroleof pages 1-3)

12.2 Disease-modifying therapies (status)

• A metabolic disorders chapter notes that oligosaccharidoses (including α-NAGA deficiency) “still lack treatment, e.g., enzyme replacement therapy,” and that “mainly palliative therapies can be provided.” (lukacs2022oligosaccharidosesandsialic pages 1-3)
• A case report states: “There is no current treatment for Schindler disease,” while noting proposed therapies. (castro2019anewcase pages 3-3)

12.3 Proposed / experimental approaches

• Pharmacological chaperones have been proposed (without clinical trial confirmation in retrieved evidence). (castro2019anewcase pages 3-3)
• Structural mapping of variants supports the rationale for chaperones that stabilize misfolded enzyme conformations. (clark2009the1.9a pages 5-7, clark2009the1.9a pages 21-22)

12.4 Clinical trials

No Kanzaki disease-specific interventional trials were identified from the retrieved clinicaltrials.gov search results.

12.5 Suggested MAXO terms (examples)

• Symptomatic treatment (MAXO:0000011; general symptomatic therapy)
• Analgesic therapy (MAXO term suggestion)
• Genetic counseling (MAXO:0000079; term suggestion)
• Enzyme activity assay / biochemical testing (diagnostic action; MAXO term suggestion) (Term IDs should be verified against MAXO; these are suggestions based on described actions.)

13. Prevention

No primary prevention is available for a Mendelian AR disorder aside from reproductive/genetic options. - Genetic counseling is emphasized as essential for families. (asadi2021theroleof pages 1-3)

Carrier screening, prenatal diagnosis, and cascade testing are plausible but were not explicitly detailed in retrieved sources.

14. Other species / natural disease

No naturally occurring veterinary Kanzaki disease analogs were identified in retrieved sources.

15. Model organisms

Evidence retrieved supports the following model and experimental systems: - Caenorhabditis elegans: a thesis describes identification of a worm ortholog (R07B7.11; later gana-1) with measurable α-N-acetylgalactosaminidase activity and outlines genetic approaches (RNAi, deletion mutants) for modeling lysosomal enzymopathies including Schindler disease. (urinovska2008…modelorganism pages 44-46, urinovska2008…modelorganisma pages 1-4) - Structural/biochemical systems: recombinant expression (insect cells) and comparisons to chicken enzyme supported mechanistic understanding of α-NAGAL. (clark2009the1.9a pages 1-2, clark2009the1.9a pages 2-4)

No explicit NAGA knockout mouse disease model was retrieved in the available texts.

Recent developments (2023–2024 priority)

1) 2024 ClinGen evaluation: NAGA–α-N-acetylgalactosaminidase deficiency is classified as Definitive for the biochemical disorder, with explicit recognition that clinical impact and expressivity remain variable. (Publication date: Nov 2024; URL: https://doi.org/10.1016/j.ymgme.2024.108593) (groopman2024assessmentofgenes pages 8-11, groopman2024assessmentofgenes pages 11-15) 2) 2024 clinical synthesis in inherited neuropathy: Kanzaki disease is included in an updated table of complex inherited neuropathies with a concise phenotype summary and identifiers (OMIM 609242; AR; NAGA), including MRI white matter abnormalities. (Publication date: Jul 2024; URL: https://doi.org/10.1097/WCO.0000000000001307) (rossor2024theevolvingspectrum pages 10-12, rossor2024theevolvingspectrum media e968f4f1)

Notes on evidence limitations

Kanzaki disease is extremely rare, and much of the detailed clinical literature consists of case reports/series. Within the retrieved corpus, Kanzaki-specific primary reports in 2023–2024 were not available, so recent content is primarily from authoritative gene-curation and expert clinical review sources rather than new patient cohorts.

References

1. (castro2019anewcase pages 1-3): Rubén García Castro, Ana María González Pérez, María Concepción Román Curto, Javier Cañueto Álvarez, Alberto Conde Ferreirós, Alex Viñolas Cuadros, David Moyano Bueno, and Antonio Javier Chamorro Fernández. A new case of schindler disease. European Journal of Case Reports in Internal Medicine, 6:1, Oct 2019. URL: https://doi.org/10.12890/2019_001269, doi:10.12890/2019_001269. This article has 12 citations.

2. (rossor2024theevolvingspectrum pages 10-12): Alexander M. Rossor, Saif Haddad, and Mary M. Reilly. The evolving spectrum of complex inherited neuropathies. Current Opinion in Neurology, 37:427-444, Jul 2024. URL: https://doi.org/10.1097/wco.0000000000001307, doi:10.1097/wco.0000000000001307. This article has 12 citations and is from a peer-reviewed journal.

3. (rossor2024theevolvingspectrum media e968f4f1): Alexander M. Rossor, Saif Haddad, and Mary M. Reilly. The evolving spectrum of complex inherited neuropathies. Current Opinion in Neurology, 37:427-444, Jul 2024. URL: https://doi.org/10.1097/wco.0000000000001307, doi:10.1097/wco.0000000000001307. This article has 12 citations and is from a peer-reviewed journal.

4. (groopman2024assessmentofgenes pages 8-11): Emily Groopman, Shruthi Mohan, Amber Waddell, Matheus Wilke, Raquel Fernandez, Meredith Weaver, Hongjie Chen, Hongbin Liu, Deeksha Bali, Heather Baudet, Lorne Clarke, Christina Hung, Rong Mao, Filippo Pinto e Vairo, Lemuel Racacho, Tatiana Yuzyuk, William J. Craigen, and Jennifer Goldstein. Assessment of genes involved in lysosomal diseases using the clingen clinical validity framework. Molecular Genetics and Metabolism, 143:108593, Nov 2024. URL: https://doi.org/10.1016/j.ymgme.2024.108593, doi:10.1016/j.ymgme.2024.108593. This article has 1 citations and is from a peer-reviewed journal.

5. (asadi2021theroleof pages 1-3): Shahin Asadi, Amir Houssein Kiani, and Mohaddeseh Mohsenifar. The role of mutations on gene naga, in schindler syndrome. Biomedical Research and Clinical Reviews, 3:01-04, Jan 2021. URL: https://doi.org/10.31579/2692-9406/029, doi:10.31579/2692-9406/029. This article has 0 citations.

6. (castro2019anewcase pages 3-3): Rubén García Castro, Ana María González Pérez, María Concepción Román Curto, Javier Cañueto Álvarez, Alberto Conde Ferreirós, Alex Viñolas Cuadros, David Moyano Bueno, and Antonio Javier Chamorro Fernández. A new case of schindler disease. European Journal of Case Reports in Internal Medicine, 6:1, Oct 2019. URL: https://doi.org/10.12890/2019_001269, doi:10.12890/2019_001269. This article has 12 citations.

7. (OpenTargets Search: Kanzaki disease,Schindler disease-NAGA): Open Targets Query (Kanzaki disease,Schindler disease-NAGA, 5 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

8. (lukacs2022oligosaccharidosesandsialic pages 1-3): Zoltan Lukacs and Michael Beck. Oligosaccharidoses and sialic acid disorders. Physician's Guide to the Diagnosis, Treatment, and Follow-Up of Inherited Metabolic Diseases, pages 437-448, Jan 2022. URL: https://doi.org/10.1007/978-3-642-40337-8_26, doi:10.1007/978-3-642-40337-8_26. This article has 0 citations.

9. (sakuraba2004structuralandimmunocytochemical pages 1-2): Hitoshi Sakuraba, Fumiko Matsuzawa, Sei-ichi Aikawa, Hirofumi Doi, Masaharu Kotani, Hiroshi Nakada, Tomoko Fukushige, and Tamotsu Kanzaki. Structural and immunocytochemical studies on α-n-acetylgalactosaminidase deficiency (schindler/kanzaki disease). Journal of Human Genetics, 49:1-8, Jan 2004. URL: https://doi.org/10.1007/s10038-003-0098-z, doi:10.1007/s10038-003-0098-z. This article has 60 citations and is from a peer-reviewed journal.

10. (makridou2025mappinglysosomalstorage pages 10-12): Anna Makridou, Evangelie Sintou, Sofia Chatzianagnosti, Sofia Gargani, Maria Eleni Manthou, Iasonas Dermitzakis, and Paschalis Theotokis. Mapping lysosomal storage disorders with neurological features by cellular pathways: towards precision medicine. Current Issues in Molecular Biology, 47:1009, Dec 2025. URL: https://doi.org/10.3390/cimb47121009, doi:10.3390/cimb47121009. This article has 0 citations.

11. (meshach2018explorationofstructural pages 1-2): D. Meshach, Paul, and bullet R Rajasekaran. Exploration of structural and functional variations owing to point mutations in α-naga. Interdisciplinary Sciences: Computational Life Sciences, 10:81-92, May 2018. URL: https://doi.org/10.1007/s12539-016-0173-8, doi:10.1007/s12539-016-0173-8. This article has 10 citations.

12. (sakuraba2004structuralandimmunocytochemical pages 5-7): Hitoshi Sakuraba, Fumiko Matsuzawa, Sei-ichi Aikawa, Hirofumi Doi, Masaharu Kotani, Hiroshi Nakada, Tomoko Fukushige, and Tamotsu Kanzaki. Structural and immunocytochemical studies on α-n-acetylgalactosaminidase deficiency (schindler/kanzaki disease). Journal of Human Genetics, 49:1-8, Jan 2004. URL: https://doi.org/10.1007/s10038-003-0098-z, doi:10.1007/s10038-003-0098-z. This article has 60 citations and is from a peer-reviewed journal.

13. (sakuraba2004structuralandimmunocytochemical pages 3-5): Hitoshi Sakuraba, Fumiko Matsuzawa, Sei-ichi Aikawa, Hirofumi Doi, Masaharu Kotani, Hiroshi Nakada, Tomoko Fukushige, and Tamotsu Kanzaki. Structural and immunocytochemical studies on α-n-acetylgalactosaminidase deficiency (schindler/kanzaki disease). Journal of Human Genetics, 49:1-8, Jan 2004. URL: https://doi.org/10.1007/s10038-003-0098-z, doi:10.1007/s10038-003-0098-z. This article has 60 citations and is from a peer-reviewed journal.

14. (keulemans1996humanalphanacetylgalactosaminidase(alphanaga) pages 3-4): J. Keulemans, A. Reuser, M. Kroos, R. Willemsen, M. Hermans, A. V. D. van den Ouweland, J. de Jong, R. Wevers, W. Renier, D. Schindler, M. Coll, A. Chabás, H. Sakuraba, Y. Suzuki, and O. V. van Diggelen. Human alpha-n-acetylgalactosaminidase (alpha-naga) deficiency: new mutations and the paradox between genotype and phenotype. Journal of Medical Genetics, 33:458-464, Jun 1996. URL: https://doi.org/10.1136/jmg.33.6.458, doi:10.1136/jmg.33.6.458. This article has 52 citations and is from a domain leading peer-reviewed journal.

15. (keulemans1996humanalphanacetylgalactosaminidase(alphanaga) pages 7-7): J. Keulemans, A. Reuser, M. Kroos, R. Willemsen, M. Hermans, A. V. D. van den Ouweland, J. de Jong, R. Wevers, W. Renier, D. Schindler, M. Coll, A. Chabás, H. Sakuraba, Y. Suzuki, and O. V. van Diggelen. Human alpha-n-acetylgalactosaminidase (alpha-naga) deficiency: new mutations and the paradox between genotype and phenotype. Journal of Medical Genetics, 33:458-464, Jun 1996. URL: https://doi.org/10.1136/jmg.33.6.458, doi:10.1136/jmg.33.6.458. This article has 52 citations and is from a domain leading peer-reviewed journal.

16. (meshach2018explorationofstructural pages 2-4): D. Meshach, Paul, and bullet R Rajasekaran. Exploration of structural and functional variations owing to point mutations in α-naga. Interdisciplinary Sciences: Computational Life Sciences, 10:81-92, May 2018. URL: https://doi.org/10.1007/s12539-016-0173-8, doi:10.1007/s12539-016-0173-8. This article has 10 citations.

17. (clark2009the1.9a pages 5-7): Nathaniel E. Clark and Scott C. Garman. The 1.9 a structure of human alpha-n-acetylgalactosaminidase: the molecular basis of schindler and kanzaki diseases. Journal of molecular biology, 393 2:435-47, Oct 2009. URL: https://doi.org/10.1016/j.jmb.2009.08.021, doi:10.1016/j.jmb.2009.08.021. This article has 83 citations and is from a domain leading peer-reviewed journal.

18. (clark2009the1.9a pages 4-5): Nathaniel E. Clark and Scott C. Garman. The 1.9 a structure of human alpha-n-acetylgalactosaminidase: the molecular basis of schindler and kanzaki diseases. Journal of molecular biology, 393 2:435-47, Oct 2009. URL: https://doi.org/10.1016/j.jmb.2009.08.021, doi:10.1016/j.jmb.2009.08.021. This article has 83 citations and is from a domain leading peer-reviewed journal.

19. (clark2009the1.9a pages 2-4): Nathaniel E. Clark and Scott C. Garman. The 1.9 a structure of human alpha-n-acetylgalactosaminidase: the molecular basis of schindler and kanzaki diseases. Journal of molecular biology, 393 2:435-47, Oct 2009. URL: https://doi.org/10.1016/j.jmb.2009.08.021, doi:10.1016/j.jmb.2009.08.021. This article has 83 citations and is from a domain leading peer-reviewed journal.

20. (clark2009the1.9a pages 21-22): Nathaniel E. Clark and Scott C. Garman. The 1.9 a structure of human alpha-n-acetylgalactosaminidase: the molecular basis of schindler and kanzaki diseases. Journal of molecular biology, 393 2:435-47, Oct 2009. URL: https://doi.org/10.1016/j.jmb.2009.08.021, doi:10.1016/j.jmb.2009.08.021. This article has 83 citations and is from a domain leading peer-reviewed journal.

21. (urinovska2008…modelorganism pages 44-46): J Uřinovská. … model organism for the study of human lysosomal enzymopathies? a study of fabry, schindler, pompe and mucopolysaccharidosis iiic diseases in c. elegans …. Unknown journal, 2008.

22. (urinovska2008…modelorganisma pages 1-4): J Uřinovská. … model organism for the study of human lysosomal enzymopathies? a study of fabry, schindler, pompe and mucopolysaccharidosis iiic diseases in c. elegans …. Unknown journal, 2008.

23. (clark2009the1.9a pages 1-2): Nathaniel E. Clark and Scott C. Garman. The 1.9 a structure of human alpha-n-acetylgalactosaminidase: the molecular basis of schindler and kanzaki diseases. Journal of molecular biology, 393 2:435-47, Oct 2009. URL: https://doi.org/10.1016/j.jmb.2009.08.021, doi:10.1016/j.jmb.2009.08.021. This article has 83 citations and is from a domain leading peer-reviewed journal.

24. (groopman2024assessmentofgenes pages 11-15): Emily Groopman, Shruthi Mohan, Amber Waddell, Matheus Wilke, Raquel Fernandez, Meredith Weaver, Hongjie Chen, Hongbin Liu, Deeksha Bali, Heather Baudet, Lorne Clarke, Christina Hung, Rong Mao, Filippo Pinto e Vairo, Lemuel Racacho, Tatiana Yuzyuk, William J. Craigen, and Jennifer Goldstein. Assessment of genes involved in lysosomal diseases using the clingen clinical validity framework. Molecular Genetics and Metabolism, 143:108593, Nov 2024. URL: https://doi.org/10.1016/j.ymgme.2024.108593, doi:10.1016/j.ymgme.2024.108593. This article has 1 citations and is from a peer-reviewed journal.

Artifacts

• Edison artifact artifact-00
• Edison artifact artifact-01
• Edison artifact artifact-02